Introduction Lumateperone is an oral atypical antipsychotic marketed under the brand name Caplyta. It is used in adults for schizophrenia, depressive episodes associated with bipolar I or bipolar II disorder, and as adjunctive therapy with antidepressants for major depressive disorder. The current U.S. prescribing information lists the recommended Caplyta dose as 42 mg orally once … Read more
Introduction Rexulti is the brand name of brexpiprazole, an oral atypical antipsychotic used in psychiatric and neuropsychiatric conditions. Pharmacologically, brexpiprazole is a serotonin-dopamine activity modulator with partial agonist activity at dopamine D2 and serotonin 5-HT1A receptors, along with antagonist activity at serotonin 5-HT2A receptors. Rexulti is used as adjunctive therapy with antidepressants for major depressive … Read more
Introduction Latuda is the brand name of lurasidone hydrochloride, an oral atypical antipsychotic drug. It is mainly used for schizophrenia and depressive episodes associated with bipolar I disorder. Pharmacologically, lurasidone is classified as a second-generation antipsychotic, also called an atypical antipsychotic. Lurasidone works by modulating dopamine and serotonin neurotransmission in the brain. The exact therapeutic … Read more
Introduction Vraylar is the brand name of cariprazine, an oral atypical antipsychotic used in schizophrenia, bipolar I disorder, and major depressive disorder as adjunctive therapy. Current prescribing information lists Vraylar for schizophrenia in adults and pediatric patients 13 years and older, acute manic or mixed episodes associated with bipolar I disorder in adults and pediatric … Read more
Introduction Caplyta is the brand name of lumateperone, an oral atypical antipsychotic used in adults for schizophrenia, depressive episodes associated with bipolar I or bipolar II disorder, and as adjunctive treatment with an antidepressant for major depressive disorder. It is not known whether Caplyta is safe and effective in children. Caplyta is important in pharmacology … Read more
Introduction Aripiprazole is a third-generation atypical antipsychotic approved for treating schizophrenia, bipolar disorder, depression (as an adjunct), Tourette’s syndrome, and irritability in autism. It is pharmacologically unique for its role as a partial agonist at dopamine D₂ and serotonin 5‑HT₁A receptors, and as an antagonist at serotonin 5‑HT₂A receptors, allowing it to modulate neurotransmission rather … Read more
Introduction Aripiprazole is an atypical antipsychotic used to treat schizophrenia, bipolar disorder, major depressive disorder (as adjunct), irritability in autism, and Tourette’s syndrome. Its unique action as a dopamine D₂ partial agonist, along with effects on serotonin receptors, sets it apart from other agents, providing antipsychotic efficacy with a lower risk of certain side effects. … Read more
